---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-22-000051"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:46:08.872069+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Exagen Q2 revenue $9.0M, net loss $13.3M; cuts 2022 guidance to $35-40M

## Summary
- AVISE CTD volume hit record 34,919 tests, up 5% YoY and 13% sequentially.
- Revenue fell to $9.0M from $12.8M YoY; gross margin dropped to 32.2% from 57.3%.
- Net loss widened to $13.3M from $6.4M loss in Q2 2021.
- 2022 revenue guidance revised to $35-40M, citing Medicare reimbursement uncertainty.
- Record 2,273 ordering providers and 797 adopters; ~100M in-network lives under contract.

## SEC filing metadata
- accession: 0001274737-22-000051
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/0001274737-22-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473722000051/exdx-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-22-000051
- JSON: https://secwatch.observer/filing/0001274737-22-000051.json
- Plain text: https://secwatch.observer/filing/0001274737-22-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.